Most protein-based therapeutics in regenerative medicine have limited success due to uncontrolled drug delivery, which can result in side effects and high costs. Based on its technology, Orio Therapeutics, based at the BioArk Technological Site in Monthey and in Monash University in Melbourne, Australia, is dedicated to unlocking the power of protein engineering and targeted drug delivery for the creation of next-generation regenerative medicines. Its technology modifies therapeutic proteins to improve delivery through controlled localization, for enhanced efficacy, reduced dosage and reduced side effects across various therapeutic areas.
The current focus lies on the development of its lead program, a groundbreaking cardioprotective drug for patients with myocardial infarction, also known as heart attack. This novel therapy aims to prevent the extensive and often irreversible damage that commonly occurs following an acute myocardial infarction. Preparations for the pre-clinical studies are underway.
Angel investors have invested half a million in the company, providing it with the required resources to advance its lead candidate into the next phase. “We are deeply grateful for the confidence our investors have placed in our team and our cutting-edge approach,” said Dr. Ziad Julier, CEO of Orio Therapeutics. “Current treatments for heart attack patients typically fall short of preventing long-term complications. With this funding, we’re one step closer to providing a solution that truly addresses this significant unmet need.”
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines